Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus R-CHOP in untreated double-expressor DLBCL
ChiCTR2000033483Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete response rate. Started Jan 2021; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2000033483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033483.